Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023
Am J Transplant. 2023 Jul;23(7):1062-1076.
doi: 10.1016/j.ajt.2023.06.004.
1 Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC. Electronic address: media@cdc.gov.
2 Westat, Rockville, Maryland.
3 Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, CDC.
4 Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health, Temple, Texas; Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas.
5 Influenza Division, National Center for Immunization and Respiratory Diseases, CDC.
6 Children's Minnesota, Minneapolis, Minnesota.
7 Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York; NewYork-Presbyterian Hospital, New York, New York.
8 HealthPartners Institute, Minneapolis, Minnesota.
9 Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah.
10 Kaiser Permanente Center for Health Research, Portland, Oregon.
11 Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California.
12 Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana; School of Medicine, Indiana University, Indianapolis, Indiana.
13 School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
14 Vanderbilt University Medical Center, Nashville, Tennessee.
15 Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana; Fairbanks School of Public Health, Indiana University, Indianapolis, Indiana.
16 Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana.